The IQVIA Institute for Human Data Science Study has developed a specific forecast for these new biosimilar molecules in oncology. The majority of the savings will be from three top-selling ...
The best way to beat persistent inflation is to invest in businesses unaffected by rising prices, like these four high-yield ...
In accordance with the biosimilar guidelines of NMPA ... a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination ...
Biosimilars and biobetters present a lucrative ... have to follow the principles and guidelines as applicable for new molecules. However, there is a potential to refer to publically available ...
In the Indian stock market, FIIs are booking profits, domestic investors are treading carefully, and valuations are stretched ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...
15 fév 2025 Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCEtm ... global biopharmaceutical company focused on developing differentiated molecules and ...
15 fév 2025 Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCEtm ... global biopharmaceutical company focused on developing differentiated molecules and ...
small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands Sterile injectable and anti-infective medicines and oral COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback